An Open-Label, Single-Arm, 3-Year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Subjects with Stargardt Disease

2025-522460-33-00 · tracked via the Priya Life Science EU tracker

Sponsor

Belite Bio Inc.

Sponsor type

Pharmaceutical company

Therapeutic area

Eye Diseases

Decision date

07/04/2026

Enrollment target

Sites

Netherlands, France, Belgium

Condition studied

Stargardt Disease

Investigational medicinal product(s)

LBS-008

Eligibility

Age group

0-17 years, 18-64 years

Sex

Female, Male

Primary endpoint

Change in DDAF (Definitely decreased autofluorescence) assessed by FAF (Fundus autofluorescence) photography, Change in QDAF (Questionably decreased autofluorescence) assessed by FAF (Fundus autofluorescence) photography, Change in DAF (Decreased autofluorescence) assessed by FAF (Fundus autofluorescence) photography

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522460-33-00 on CTIS ↗ ← All trials in the EU